A Phase I Dose Escalation Study of Hypofractionated IMRT Field-in-Field Boost for Newly Diagnosed Glioblastoma Multiforme
Arta M. Monjazeb(University of California Davis Medical Center), Edward G. Shaw(Wake Forest University), Michael D. Chan(Wake Forest University), Stephen B. Tatter(Atrium Health Wake Forest Baptist), Deandra Ayala(Wake Forest University), Kevin P. McMullen(Radiation Oncology Associates), L. Douglas Case(Wake Forest University), J. Daniel Bourland(Radiation Oncology Associates), Courtney A. Jensen(Wake Forest University), Thomas L. Ellis(Wake Forest University), G. J. Lesser(Wake Forest University)
International Journal of Radiation Oncology*Biology*Physics
January 14, 2011
Cited by 43
Related Papers
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
|New England Journal of Medicine|2016|1k
Radiation-induced brain injury: A review
|Frontiers in Oncology|2012|686
Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion
|Nature Communications|2022|243
Subsecond dopamine fluctuations in human striatum encode superposed error signals about actual and counterfactual reward
|Proceedings of the National Academy of Sciences|2015|239